Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECP-O66
- Development stage
- Preclinical
- Lead developer
- ECP
- Modality
- Small Molecules
01
Overview
ECP-O66 is a preclinical-stage small molecule therapeutic candidate being developed by ECP Pharma for the treatment of amnestic mild cognitive impairment (aMCI). As part of ECP Pharma's focus on the endocannabinoid system (ECS), ECP-O66 is designed to modulate ECS pathways to potentially provide neuroprotective effects and improve cognitive outcomes in patients experiencing early-stage memory loss. The drug is intended to target biological pathways that may slow cognitive decline or improve memory function in patients at high risk of progressing to more severe forms of dementia, such as Alzheimer's disease. As of 2024, the program remains in the preclinical stage of research and development.
Beyond the preview
Go deeper on ECP-O66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECP-O66.